Abatacept
Abatacept
Definition
A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.
Also known as ABATACEPT, BMS-188667, CTL A4-Ig B7 Inhibitor, CTLA4-Ig, cytotoxic T lymphocyte-associated antigen-4, Orencia, RG2077 — per NCIT
Also identified as
- ATC L04AA24 per RXNORM
- NCIT NCIT:C28898 per NCIT
- SCTID 421412005 per RXNORM
- SCTID 421777009 per RXNORM
- UNII 7D0YB67S97 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Juvenile idiopathic arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
| Psoriatic arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
| Rheumatoid arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone element | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Skeletal joint | may treat a disease of this organ | DERIVED · CC BY 4.0 |
3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.